Vanguard Group Inc. Acquires 75,631 Shares of Solventum Co. (NYSE:SOLV)

Vanguard Group Inc. lifted its holdings in shares of Solventum Co. (NYSE:SOLV) by 0.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,266,893 shares of the company’s stock after acquiring an additional 75,631 shares during the period. Vanguard Group Inc. owned approximately 9.42% of Solventum worth $1,074,591,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SOLV. State Street Corp boosted its stake in Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC grew its holdings in Solventum by 4.0% during the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after buying an additional 128,317 shares in the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in Solventum in the 3rd quarter valued at $125,488,000. Boston Partners purchased a new stake in Solventum in the 4th quarter valued at $110,378,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after acquiring an additional 3,745 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on SOLV shares. Wells Fargo & Company upped their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Morgan Stanley lifted their target price on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th. Mizuho upped their target price on Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Finally, Bank of America upped their price objective on Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $79.86.

Solventum Stock Performance

Shares of SOLV opened at $74.78 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market cap of $12.94 billion and a PE ratio of 27.19. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The stock’s fifty day moving average price is $75.51 and its two-hundred day moving average price is $71.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.